Aduro Biotech, Inc. (NASDAQ:ADRO) COO Gregory W. Schafer sold 20,000 shares of the business’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $10.75, for a total transaction of $215,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Shares of Aduro Biotech, Inc. (ADRO) traded down 2.027% on Thursday, hitting $10.875. 173,917 shares of the stock were exchanged. The company’s 50 day moving average is $11.17 and its 200-day moving average is $10.94. The stock’s market cap is $811.41 million. Aduro Biotech, Inc. has a 52-week low of $8.75 and a 52-week high of $15.53.

Aduro Biotech (NASDAQ:ADRO) last issued its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.27) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by ($0.02). The business had revenue of $5.90 million for the quarter, compared to analyst estimates of $3.98 million. Aduro Biotech had a negative return on equity of 43.92% and a negative net margin of 609.58%. The firm’s revenue for the quarter was down 84.9% compared to the same quarter last year. During the same period in the prior year, the company posted $0.03 EPS. Analysts predict that Aduro Biotech, Inc. will post ($1.35) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This article was first posted by Marea Informative and is the property of of Marea Informative. If you are accessing this article on another site, it was illegally copied and reposted in violation of United States and international copyright legislation. The legal version of this article can be read at http://www.mareainformativa.com/aduro-biotech-inc-adro-coo-gregory-w-schafer-sells-20000-shares-of-stock/117889/.

Several equities research analysts have recently commented on ADRO shares. HC Wainwright restated a “buy” rating and issued a $18.00 price target on shares of Aduro Biotech in a report on Wednesday, September 27th. BidaskClub upgraded shares of Aduro Biotech from a “hold” rating to a “buy” rating in a report on Tuesday, July 25th. William Blair restated an “outperform” rating on shares of Aduro Biotech in a report on Monday. Zacks Investment Research upgraded shares of Aduro Biotech from a “hold” rating to a “buy” rating and set a $13.00 price target for the company in a report on Tuesday, July 4th. Finally, Cowen and Company started coverage on shares of Aduro Biotech in a report on Tuesday, July 18th. They issued an “outperform” rating for the company. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $19.00.

Several institutional investors and hedge funds have recently modified their holdings of the company. Legal & General Group Plc raised its holdings in Aduro Biotech by 11.2% in the second quarter. Legal & General Group Plc now owns 10,359 shares of the biotechnology company’s stock valued at $118,000 after acquiring an additional 1,043 shares in the last quarter. Parametric Portfolio Associates LLC raised its holdings in Aduro Biotech by 15.9% in the first quarter. Parametric Portfolio Associates LLC now owns 15,424 shares of the biotechnology company’s stock valued at $166,000 after acquiring an additional 2,119 shares in the last quarter. Tudor Investment Corp ET AL raised its holdings in Aduro Biotech by 34.8% in the first quarter. Tudor Investment Corp ET AL now owns 15,436 shares of the biotechnology company’s stock valued at $166,000 after acquiring an additional 3,984 shares in the last quarter. Voya Investment Management LLC raised its holdings in Aduro Biotech by 15.3% in the second quarter. Voya Investment Management LLC now owns 18,935 shares of the biotechnology company’s stock valued at $216,000 after acquiring an additional 2,515 shares in the last quarter. Finally, American International Group Inc. raised its holdings in Aduro Biotech by 7.1% in the first quarter. American International Group Inc. now owns 21,840 shares of the biotechnology company’s stock valued at $235,000 after acquiring an additional 1,447 shares in the last quarter. 35.05% of the stock is currently owned by institutional investors and hedge funds.

About Aduro Biotech

Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.

Insider Buying and Selling by Quarter for Aduro Biotech (NASDAQ:ADRO)

Receive News & Stock Ratings for Aduro Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro Biotech Inc. and related stocks with our FREE daily email newsletter.